Participated · Equity · Mar 2026

Founded in 2017 as a spin-off from Graz University of Technology, Austria-based VALANX Biotech engineers site-specific protein conjugations through its proprietary GoldenSite platform. The technology enables precise, reproducible attachment of therapeutic payloads to antibodies, aiming to widen the therapeutic window of antibody-drug conjugates (ADCs). VALANX’s lead program, VLX-ADC-001, targets the LIV-1 protein frequently expressed in metastatic triple-negative breast cancer, a tumor type with limited treatment options. The company intends to complete candidate selection for VLX-ADC-001 by June 2026 and to bring GoldenSite to GMP readiness for future clinical work and partnerships. Beyond the lead asset, VALANX plans to apply GoldenSite to additional ADC and protein-conjugate programs and to seek collaborations with other ADC developers. The most recent €3 million financing strengthens its balance sheet for preclinical studies, manufacturing scale-up, and business development activities. Key backers include strategic investor FUJIFILM Corporation, oncology-focused Foundation Fournier-Majoie, and repeat supporters such as xista science ventures, Tecnet Equity, and SOSV.

Participated · Series A · Dec 2023

Tome Biosciences develops programmable genomic integration (PGI) technologies to insert genetic sequences of any size at specific genomic locations for integrative gene and cell therapies. Its lead PGI approach, integrase-mediated PGI (I-PGI), is based on PASTE technology discovered by co‑founders Omar Abudayyeh and Jonathan Gootenberg at MIT and combines CRISPR/Cas9 site-specificity with integrases to insert DNA without double-strand breaks. Tome has demonstrated site-specific insertions of more than 30 kb in multiple dividing and non-dividing cell types and can multiplex edits to enable complex cell engineering. The company holds an exclusive license to the core PASTE technology and lists U.S. patents 11,572,556; 11,827,881; and 11,834,658. Led by President and CEO Rahul Kakkar, Tome plans to use the new capital to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases. The company raised $213M in Series A and Series B financings and operates in the genomic medicines field focused on delivering curative therapies.

Participated · Series E · May 2021

24M delivers battery innovations by reinventing battery technologies and manufacturing methods through its SemiSolid™ and Unit Cell manufacturing platform. Its chemistry-agnostic design, process, and platform aim to reduce manufacturing costs while improving safety, range, performance, and recyclability. The company says its technology set addresses long-standing industry challenges in preferred energy storage products. 24M plans to accelerate commercialization and mass production of its offerings, including acquiring and opening a new R&D and pilot manufacturing plant in Rayong, Thailand. The company is headquartered in Cambridge, Mass. The recent financing brings total funding to over $500 million, supporting its push toward scaled production and market rollout. 24M develops a chemistry-agnostic SemiSolid™ manufacturing platform intended to lower the cost and improve performance of energy storage. The company has commercially demonstrated its ultra-thick SemiSolid electrode architecture with high energy density using lithium‑ion chemistry. 24M plans to adapt that platform to sodium metal batteries aimed at low‑cost, fast‑charging and wide‑temperature EV applications. It will partner with MIT and Carnegie Mellon University to apply a cell design that includes an ultra‑thick cobalt‑ and nickel‑free sodium cathode, an advanced wide‑temperature fast‑charging electrolyte developed with machine learning and high‑throughput screening, and a sodium super ionic conductor. The company is headquartered in Cambridge, Mass. Company leadership includes president and CEO Naoki Ota and Dr. JunZheng Chen, director of advanced R&D. 24M Technologies builds SemiSolid lithium‑ion cells and a redesigned manufacturing approach intended to reduce battery cost while improving performance. The company is advancing next‑generation high energy density lithium metal anode cells using its SemiSolid platform. 24M plans to combine a lithium metal anode with a SemiSolid cathode to deliver lower cost, superior power and improved energy density for electric aviation applications. The team is developing and scaling a commercial, modular pilot line for customer validation with a clear path to gigascale production capacity. A recent $9 million ARPA‑E award is intended to accelerate commercialization and rapid market entry. 24M is headquartered in Cambridge, Mass., and is founded and led by industry inventors and scientists including co‑founder Dr. Yet‑Ming Chiang and President & CEO Naoki Ota. 24M commercializes its SemiSolid™ lithium‑ion manufacturing platform that mixes electrolyte with active materials to form a binder‑free, clay‑like slurry. The process eliminates significant inactive materials and capital‑intensive steps such as drying and electrolyte filling, aiming to dramatically reduce manufacturing cost. 24M says the platform delivers market‑leading price‑performance and that it has improved cell performance and safety. The company is working with licensee partners, including Kyocera and GPSC, which have expanded commercial operations. Proceeds from the financing will be used to commercialize the SemiSolid manufacturing process and expand technology development programs for grid storage and electric vehicle applications. 24M is headquartered in Cambridge, Mass., and is led by industry inventors, scientists and entrepreneurs. 24M commercializes a SemiSolid lithium-ion battery design and a novel, capital-efficient manufacturing process that uses electrolyte as the processing solvent. The process eliminates steps such as drying, solvent recovery, calendaring and electrolyte filling, and reduces the need for inactive materials like copper, aluminum and separator. 24M says this approach yields a structural bill-of-materials advantage and lower manufacturing cost while enabling high energy density cell designs not previously possible. The company has used a semi-automated pilot facility to advance cell design and production readiness. 24M is targeting both the low-cost grid market and the high energy density requirements of the EV market and says it is ready to scale globally. The company is headquartered in Cambridge, Mass.